GSK Bets $10.6 Billion on Cancer Drugs as It Leaves Consumer Health Behind

GSK paid $10.6 billion in cash for Nuvalent, a cancer drug maker, on June 9, 2026. After spinning off its consumer health business in 2022, GSK is now doubling down on specialty medicines—drugs that command premium prices and face less competition. Nuvalent brings three lung cancer candidates to the table. The price tag reflects a bet on future profits, not current earnings.